ArticleFrontiers in oncology2025
Peripheral blood metabolic composite score based on peripheral blood metabolism can be used as an assessment of recurrence after surgery in patients with locally advanced gastric cancer: a novel and promising index.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative recurrence remains a major challenge in patients with locally advanced gastric cancer (LAGC). Identifying reliable biomarkers for predicting recurrence can guide clinical decision-making and improve patient outcomes. This study aimed to investigate the association between four peripheral blood metabolic markers and postoperative recurrence in LAGC patients, and to develop a predictive model based on these markers. Methods: This retrospective cohort study analyzed data from 1,040 patients with LAGC who underwent radical surgical resection between January 2010 and December 2019. Peripheral blood metabolic indicators, including low-density lipoprotein/high-density lipoprotein (LHR), cholesterol/high-density lipoprotein (TCHR), triglycerides/high-density lipoprotein (TGHR), and triglycerides × fasting blood glucose (TyG), were used to assess metabolic status. Multivariable regression and survival analysis were performed to assess the prognostic value of these markers. A nomogram combining metabolic markers and clinical factors was developed and validated for predicting postoperative recurrence. Results: High levels of LHR, TCHR, TGHR, and TyG were significantly associated with increased risk of postoperative recurrence in LAGC patients (P < 0.001). Multivariable analysis identified TNM stage, pathological type, systemic immune inflammation index (SII), and metabolic score as independent predictors of recurrence. A predictive model incorporating these factors demonstrated superior performance compared to clinical features alone, with an area under the curve (AUC) of 0.867 (95% CI: 0.836-0.897) in the training set, 0.887 (95% CI: 0.844-0.929) in internal validation set, 0.859 (95% CI: 0.817-0.899) in the external validation set. Patients with high metabolic scores had significantly worse overall survival (OS) and disease-free survival (DFS), further supporting the model's prognostic value. Conclusions: Peripheral blood metabolic markers, particularly LHR, TCHR, TGHR, and TyG, are valuable predictors of postoperative recurrence in LAGC patients. The combined predictive model, integrating metabolic markers and clinical features, provides an effective tool for personalized risk stratification and may assist in optimizing postoperative management in LAGC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.